Pharmaceutical group Siegfried has announced that it will build a new research and development laboratory on its Evionnaz site, in the canton of Valais. Specialized in the production of active pharmaceutical ingredients (APIs), intermediates and finished dosage forms, pharmaceutical group Siegfried has eleven sites in seven countries on three continents.
With a presence in the city of Evionnaz since 1904, this location is already recognized within the group as a key site for processing new projects for its clients in the pharmaceutical industry. This new investment will further strengthen the group’s position in the region.
The new four-story building dedicated to research and development will be adjacent to Siegfried's existing site in Evionnaz. Although the group did not communicate on an exact amount, it mentioned an "investment of several dozens of millions of Swiss francs”.
Siegfried hopes to begin construction quickly and launch the building's operations by 2024. Over time, the company expects to create about 40 new jobs on the site.
"These will be mainly chemist and laboratory technician positions, both for synthesis and analysis," said Siegfried, which currently employs 370 people in Evionnaz.
The Evionnaz site produces active ingredients for the pharmaceutical industry. It is also one of the main sites of the Siegfried Group for the launch of new projects. "In this context, the increase in our laboratory capacity for research and development of industrial processes and analytical development is a key component in meeting the demands of our customers," explained Valérie Besse, spokesperson for Siegfried.
